Journal article
Pirtobrutinib in Post-cBTKi CLL/SLL: ∼30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Lindsey E Roeker, Krish Patel, Toby A Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S Tam, John F Seymour, Benoit Tessoulin, Nirav N Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C Coombs, Ian W Flinn, Manish Patel, Sunita D Nasta, Jonathon B Cohen Show all
BLOOD | ELSEVIER | Published : 2023
Abstract
Background: The treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has benefited from covalent (c) Bruton tyrosine kinase inhibitors (BTKi), however, therapy can fail due to progression or intolerance. Sequential treatment with B-cell lymphoma 2 protein inhibitor (BCL2i) venetoclax, either as monotherapy or combined with an anti-CD20 monoclonal antibody, has been the primary treatment option for CLL/SLL patients (pts) whose disease has progressed on cBTKi. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that demonstrated promising efficacy in patients with relapsed or refractory CLL/SLL (Mato et al, NEJM, 2023). Here, we report on the efficacy ..
View full abstract